Answer
Skin reactions occurred in approximately 94% of 2,224 metastatic colorectal cancer trial patients receiving panitumumab (Vectibix) alone or with chemotherapy; most were mild to moderate, with 23% severe (grade 3) and less than 1% life-threatening (grade 4).
Sources for this answer
- Vectibix 20 mg/mL concentrate for solution for infusionAmgen Ltd · emc · SmPC §4.8 Undesirable effects · Version 27Document updated
Sources checked